Clinical Outcomes of Drug-Coated Balloons in Coronary Artery Disease Unsuitable for Drug-Eluting Stent Implantation.
Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
Randomized comparative study of diamond-like carbon coated stainless steel stent versus uncoated stent implantation in patients with coronary artery disease.
Drug-Coated Balloons in the Management of Coronary Artery Disease.
Korjian S, McCarthy KJ, Larnard EA, Cutlip DE, McEntegart MB, Kirtane AJ, Yeh RW.
Circ Cardiovasc Interv. 2024 May;17(5):e013302. doi: 10.1161/CIRCINTERVENTIONS.123.013302. Epub 2024 May 21.
Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial.
Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, Wiebe J, Joner M, Hochholzer W, Laugwitz KL, Schunkert H, Kastrati A, Kufner S.
Eur Heart J. 2023 Apr 17;44(15):1343-1357. doi: 10.1093/eurheartj/ehad026.
Coronary Artery Dissection in Drug-Coated Balloon Angioplasty: Incidence, Predictors, and Clinical Outcomes.
Gitto M, Leone PP, Gioia F, Chiarito M, Latini A, Tartaglia F, Kilic ID, Rossi ML, Regazzoli D, Gasparini G, Cozzi O, Sticchi A, Condorelli G, Reimers B, Stefanini G, Mangieri A, Colombo A.
Am J Cardiol. 2025 Mar 15;239:28-35. doi: 10.1016/j.amjcard.2024.12.008. Epub 2024 Dec 10.
Coronary stent failure: role of a blended approach with drug-coated balloons for complex lesions.
Cortese B, Sanchez-Jimenez E, Lazar L.
Minerva Cardiol Angiol. 2024 Jun;72(3):266-280. doi: 10.23736/S2724-5683.22.06172-5. Epub 2023 Mar 20.
Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C, Desmet W, Donohoe DJ, Ormiston JA, Knape C, Bezerra H, Lansky A, Wijns W; DESSOLVE II Investigators.
Catheter Cardiovasc Interv. 2015 Dec 1;86(7):1141-50. doi: 10.1002/ccd.25610. Epub 2015 Sep 22.
Clinical Outcomes of Drug-Coated Balloons in Coronary Artery Disease Unsuitable for Drug-Eluting Stent Implantation.
Iijima R, Kougame N, Hara H, Moroi M, Nakamura M.
Circ J. 2018 Jul 25;82(8):2025-2031. doi: 10.1253/circj.CJ-18-0121. Epub 2018 Jun 12.
Sirolimus-coated balloon versus everolimus-eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trial.
Greco A, Sciahbasi A, Abizaid A, Mehran R, Rigattieri S, de la Torre Hernandez JM, Alfonso F, Cortese B.
Catheter Cardiovasc Interv. 2022 Oct;100(4):544-552. doi: 10.1002/ccd.30358. Epub 2022 Sep 2.
Expanding indications for drug-coated balloons in coronary artery disease.
Greco A, Di Leo G, Spagnolo M, Giacoppo D, Capodanno D.
Expert Rev Med Devices. 2025 Apr;22(4):321-338. doi: 10.1080/17434440.2025.2474179. Epub 2025 Mar 7.
Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?
Tijssen RYG, Kraak RP, Lu H, Mifek JG, Carlyle WC, Donohoe DJ, De Winter RJ, Koch KT, Wykrzykowska JJ.
Expert Rev Med Devices. 2017 May;14(5):325-334. doi: 10.1080/17434440.2017.1318057. Epub 2017 Apr 24.
Angioscopic assessments and clinical outcomes one year after polymer-free biolimus A9-coated coronary stent implantation.
Tsujimura T, Ishihara T, Okuno S, Iida O, Kurata N, Asai M, Masuda M, Okamoto S, Nanto K, Kanda T, Matsuda Y, Hata Y, Mano T.
J Cardiol. 2021 May;77(5):457-464. doi: 10.1016/j.jjcc.2020.10.002. Epub 2020 Oct 26.
